2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
628
Stomach Neoplasms
76
Neoplasm Metastasis
59
Neoplasms
39
HER2-positive Breast Cancer
33
Breast Neoplasms, Male
30
Colorectal Neoplasms
28
Brain Neoplasms
25
Carcinoma, Non-Small-Cell Lung
21
Inflammatory Breast Neoplasms
20
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Triple Negative Breast Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Ovarian Neoplasms
10
Colonic Neoplasms
10
Urinary Bladder Neoplasms
9
Rectal Neoplasms
9
Prostatic Neoplasms
9
Cardiotoxicity
8
Adenocarcinoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Breast Diseases
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Sarcoma
6
Interventions
Drug Therapy
3
Temozolomide
2
Radiotherapy
2
Radiosurgery
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
sacubitril and valsartan sodium hydrate drug combination
1
icotinib
1
dostarlimab
1
beta Carotene
1
avelumab
1
alpha-Tocopherol
1
Varenicline
1
Tyrosine Kinase Inhibitors
1
Trastuzumab
1
Tobacco Use Cessation Devices
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Semen Analysis
1
Registries
1
Probiotics
1
Patient Reported Outcome Measures
1
Panitumumab
1
Nicotine Chewing Gum
1
Myofascial Release Therapy
1
Megestrol Acetate
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
Trastuzumab
×
Clear all
NCT03199300
2025-12-11
InvestiCAT
University Medical Center Groningen
Active not recruiting
20 enrolled